Eurand, Inc. v. Mylan Pharms. Inc. (In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.), Appeal No. 2011-1399

• Decision Date: 01 May 2012
• Docket Number: Appeal No. 2011-1399,Appeal No. 2011-1409
• Parties: IN RE CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION EURAND, INC., CEPHALON, INC., and ANESTA AG, Plaintiffs-Cross Appellants, v. MYLAN PHARMACEUTICALS INC. and MYLAN INC., Defendants-Appellants, and BARR LABORATORIES, INC., TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICAL INDUSTRIES LTD., Defendants-Appellees.
• Court: United States Courts of Appeals. United States Court of Appeals for the Federal Circuit

IN RE CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION

EURAND, INC., CEPHALON, INC., and ANESTA AG, Plaintiffs-Cross Appellants, v. MYLAN PHARMACEUTICALS INC. and MYLAN INC., Defendants-Appellants, and BARR LABORATORIES, INC., TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICAL INDUSTRIES LTD., Defendants-Appellees.

Appeal No. 2011-1399

Appeal No. 2011-1409

United States Court of Appeals for the Federal Circuit

Decided: April 16, 2012

Filed: May 1, 2012

ERRATA

Precedential Opinion

Please make the following additions:

Page 2, Of counsel on the brief for plaintiff-cross appellant was Tryn T. Stimart, Cooley Godward Kronish LLP, of Washington, DC.

Robert L. Byer, Duane Morris LLP, of Pittsburg, Pennsylvania, for amici curiae Gregory Dolin and Robert C. Kahrl. With him on the brief were Kristina Caggiano and Elese Hanson.